Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience

ConclusionsOur data furtherly support peptide receptor radionuclide therapy as a safe and effective treatment of patients affected by pulmonary neuroendocrine neoplasms allowing disease control in about 71% of patients without showing significant toxicity. Other studies are needed to confirm our results.

http://link.springer.com/10.1007/s13139-020-00679-y

Source: Nuclear Medicine and Molecular Imaging - January 12, 2021 Category: Nuclear Medicine Source Type: research